Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Agomab Therapeutics NV

Late-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn’s to be Presented at Digestive Disease Week® 2025
From Agomab Therapeutics NV
Via Business Wire
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
From Agomab Therapeutics NV
Via Business Wire
Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-Focused Pipeline
From Agomab Therapeutics NV
Via Business Wire
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
From Agomab Therapeutics NV
Via Business Wire
Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
From Agomab Therapeutics NV
Via Business Wire
Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis
From Agomab Therapeutics NV
Via Business Wire
Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
From Agomab Therapeutics NV
Via Business Wire
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
From Agomab Therapeutics NV
Via Business Wire
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
From Agomab Therapeutics NV
Via Business Wire
Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
From Agomab Therapeutics NV
Via Business Wire
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
From Agomab Therapeutics NV
Via Business Wire
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
From Agomab Therapeutics NV
Via Business Wire
Agomab Therapeutics Completes Acquisition of Origo Biopharma
From Agomab Therapeutics NV
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.